LivaNova PLC

LivaNova PLC is a global medical technology company that designs, develops, manufactures, markets, and sells medical products, therapies, and services. The company is organized under the laws of England and Wales, headquartered in London, England, and its ordinary shares trade on Nasdaq under the symbol "LIVN." LivaNova operates through two reportable segments: Cardiopulmonary and Neuromodulation. The "Other" category includes non-allocated corporate expenses and non-cannula results from the former ACS segment, which was wound down during 2024. The Cardiopulmonary segment focuses on the design, development, manufacture, marketing, and sale of cardiopulmonary products and related services. Key products include heart-lung machines (HLMs), oxygenators, autotransfusion systems, perfusion tubing systems, and cannulae. This segment features the Essenz Perfusion System, an HLM with an embedded patient monitor and sensing technology for data-driven decisions during cardiopulmonary bypass (CPB) procedures. CPB is used in heart-related medical procedures, such as coronary artery bypass grafting and valve surgeries, to oxygenate and circulate a patient's blood. LivaNova's products support CPB for neonatal, pediatric, and adult patients. The HLM product group specifically includes HLMs, heater-coolers, related cardiac surgery equipment, and maintenance and technical services. HLMs temporarily take over heart and/or lung functions, circulating blood and oxygen to the body while the heart is stopped during cardiac surgery.